Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 79

Similar articles for PubMed (Select 15837746)

1.

Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer.

Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, Tsushima F, Otsuki N, Yagita H, Azuma M, Nakajima Y.

Clin Cancer Res. 2005 Apr 15;11(8):2947-53.

2.

Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.

Menke J, Lucas JA, Zeller GC, Keir ME, Huang XR, Tsuboi N, Mayadas TN, Lan HY, Sharpe AH, Kelley VR.

J Immunol. 2007 Dec 1;179(11):7466-77.

3.

Protective role of programmed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models.

Wang CJ, Chou FC, Chu CH, Wu JC, Lin SH, Chang DM, Sytwu HK.

Diabetes. 2008 Jul;57(7):1861-9. doi: 10.2337/db07-1260. Epub 2008 Apr 16.

4.

Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer.

Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M, Nakajima Y.

Clin Cancer Res. 2007 Apr 1;13(7):2151-7.

5.

Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.

Brown JA, Dorfman DM, Ma FR, Sullivan EL, Munoz O, Wood CR, Greenfield EA, Freeman GJ.

J Immunol. 2003 Feb 1;170(3):1257-66.

6.

Expression of programmed death 1 and its ligands in the liver of autoimmune hepatitis C57BL/6 mice.

Cao J, Liu FX, Yu MX.

Chin Med J (Engl). 2009 Aug 20;122(16):1941-6.

PMID:
19781375
7.
8.

PD-L2 is a second ligand for PD-1 and inhibits T cell activation.

Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, Greenfield EA, Bourque K, Boussiotis VA, Carter LL, Carreno BM, Malenkovich N, Nishimura H, Okazaki T, Honjo T, Sharpe AH, Freeman GJ.

Nat Immunol. 2001 Mar;2(3):261-8.

PMID:
11224527
9.

[Expression of CD80, CD86, TGF-beta1 and IL-10 mRNA in the esophageal carcinoma].

Yang WF, Yu JM, Zuo WS, Wang SZ.

Zhonghua Zhong Liu Za Zhi. 2006 Oct;28(10):762-5. Chinese.

PMID:
17366789
10.

The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis.

Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M, Klareskog L, Catrina AI, Sidiropoulos P, Boumpas DT.

Arthritis Rheum. 2010 Jul;62(7):1870-80. doi: 10.1002/art.27500.

11.

Negative regulation of T-cell function by PD-1.

Zha Yy, Blank C, Gajewski TF.

Crit Rev Immunol. 2004;24(4):229-37. Review.

PMID:
15588223
12.

PD-1-PD-L1 pathway is involved in suppressing alloreactivity of heart infiltrating t cells during murine gvhd across minor histocompatibility antigen barriers.

Schilbach K, Schick J, Wehrmann M, Wollny G, Simon P, Schlegel PG, Eyrich M.

Transplantation. 2007 Jul 27;84(2):214-22. Erratum in: Transplantation. 2008 Mar 27;85(6):910. Perikles, Simon [corrected to Simon, Perikles].

PMID:
17667813
13.

Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.

Hamanishi J, Mandai M, Iwasaki M, Okazaki T, Tanaka Y, Yamaguchi K, Higuchi T, Yagi H, Takakura K, Minato N, Honjo T, Fujii S.

Proc Natl Acad Sci U S A. 2007 Feb 27;104(9):3360-5. Epub 2007 Feb 21.

14.
15.

Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.

Blank C, Gajewski TF, Mackensen A.

Cancer Immunol Immunother. 2005 Apr;54(4):307-14. Epub 2004 Dec 15. Review.

PMID:
15599732
16.

Expression of PD-1, PD-L1, and PD-L2 in the liver in autoimmune liver diseases.

Mataki N, Kikuchi K, Kawai T, Higashiyama M, Okada Y, Kurihara C, Hokari R, Kawaguchi A, Nagao S, Kondo T, Itoh K, Miyakawa H, Miura S.

Am J Gastroenterol. 2007 Feb;102(2):302-12.

PMID:
17311651
17.

Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers.

Nakanishi J, Wada Y, Matsumoto K, Azuma M, Kikuchi K, Ueda S.

Cancer Immunol Immunother. 2007 Aug;56(8):1173-82. Epub 2006 Dec 22.

PMID:
17186290
18.

Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma.

Gao Q, Wang XY, Qiu SJ, Yamato I, Sho M, Nakajima Y, Zhou J, Li BZ, Shi YH, Xiao YS, Xu Y, Fan J.

Clin Cancer Res. 2009 Feb 1;15(3):971-9. doi: 10.1158/1078-0432.CCR-08-1608.

19.

Tissue expression of PD-L1 mediates peripheral T cell tolerance.

Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH, Sharpe AH.

J Exp Med. 2006 Apr 17;203(4):883-95. Epub 2006 Apr 10.

20.

Programmed death-1 targeting can promote allograft survival.

Ozkaynak E, Wang L, Goodearl A, McDonald K, Qin S, O'Keefe T, Duong T, Smith T, Gutierrez-Ramos JC, Rottman JB, Coyle AJ, Hancock WW.

J Immunol. 2002 Dec 1;169(11):6546-53.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk